NasdaqGS:PBYI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care.


Snowflake Analysis

Mediocre balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Puma Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PBYI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.5%

PBYI

-1.2%

US Biotechs

0.7%

US Market


1 Year Return

5.7%

PBYI

34.0%

US Biotechs

20.1%

US Market

Return vs Industry: PBYI underperformed the US Biotechs industry which returned 34% over the past year.

Return vs Market: PBYI underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

PBYIIndustryMarket
7 Day-3.5%-1.2%0.7%
30 Day0.4%-4.4%6.4%
90 Day-21.6%4.5%20.1%
1 Year5.7%5.7%36.1%34.0%22.6%20.1%
3 Year-87.6%-87.6%33.4%27.1%45.1%35.7%
5 Year-89.0%-89.0%8.5%0.8%79.7%60.3%

Price Volatility Vs. Market

How volatile is Puma Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Puma Biotechnology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PBYI ($9.91) is trading below our estimate of fair value ($60.98)

Significantly Below Fair Value: PBYI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PBYI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PBYI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PBYI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PBYI is overvalued based on its PB Ratio (16.8x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Puma Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

69.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBYI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: PBYI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PBYI's is expected to become profitable in the next 3 years.

Revenue vs Market: PBYI's revenue (8.8% per year) is forecast to grow slower than the US market (9.5% per year).

High Growth Revenue: PBYI's revenue (8.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PBYI's Return on Equity is forecast to be low in 3 years time (0.4%).


Next Steps

Past Performance

How has Puma Biotechnology performed over the past 5 years?

22.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PBYI is currently unprofitable.

Growing Profit Margin: PBYI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PBYI is unprofitable, but has reduced losses over the past 5 years at a rate of 22.5% per year.

Accelerating Growth: Unable to compare PBYI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PBYI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).


Return on Equity

High ROE: PBYI has a negative Return on Equity (-177.85%), as it is currently unprofitable.


Next Steps

Financial Health

How is Puma Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: PBYI's short term assets ($159.2M) exceed its short term liabilities ($94.5M).

Long Term Liabilities: PBYI's short term assets ($159.2M) exceed its long term liabilities ($145.9M).


Debt to Equity History and Analysis

Debt Level: PBYI's debt to equity ratio (412.7%) is considered high.

Reducing Debt: Insufficient data to determine if PBYI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PBYI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PBYI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Puma Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PBYI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PBYI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PBYI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PBYI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PBYI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Alan Auerbach (50 yo)

8.83yrs

Tenure

US$3,755,322

Compensation

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman, Chief Executive Officer and President since October 4, 2011 and serves as its Secretary. Mr. Auerbach is ...


CEO Compensation Analysis

Compensation vs Market: Alan's total compensation ($USD3.76M) is above average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alan Auerbach
Founder8.83yrsUS$3.76m10.46%
$ 41.2m
Maximo Nougues
CFO & Principal Accounting Officer1.75yrsUS$665.80kno data
Richard Bryce
Chief Medical & Scientific Officer3yrsUS$1.33m0.069%
$ 273.0k
Douglas Hunt
Senior Vice President of Regulatory Affairs2.58yrsUS$1.38m0.022%
$ 84.7k
Mariann Ohanesian
Senior Director of Investor Relations8.75yrsno datano data
Charon Spencer
Vice President of Human Resourcesno datano datano data
Jeffrey Ludwig
Chief Commercial Officer0.42yrno datano data

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: PBYI's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alan Auerbach
Founder8.83yrsUS$3.76m10.46%
$ 41.2m
Jay Moyes
Lead Independent Directorno dataUS$357.20k0.039%
$ 154.0k
Michael Miller
Independent Director2.5yrsUS$327.20k0.063%
$ 247.1k
Troy Wilson
Independent Director6.83yrsUS$342.20k0.0023%
$ 8.9k
Adrian Senderowicz
Independent Director5yrsUS$337.20k0.038%
$ 151.2k
Hugh O'Dowd
Independent Director0.83yrUS$461.94kno data
Brian Stuglik
Director0.083yrno datano data
Ann Miller
Independent Director0.75yrUS$834.57kno data

2.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: PBYI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PBYI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

Puma Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Puma Biotechnology, Inc.
  • Ticker: PBYI
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$393.594m
  • Shares outstanding: 39.68m
  • Website: https://www.pumabiotechnology.com

Number of Employees


Location

  • Puma Biotechnology, Inc.
  • 10880 Wilshire Boulevard
  • Suite 2150
  • Los Angeles
  • California
  • 90024
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PBYINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2012
0PBDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2012

Biography

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatm ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 01:22
End of Day Share Price2020/08/13 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.